Therapeutic Asset Ratings
132 results matching 1 filter
133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Metformin
Metastatic Solid Tumor
Turning Point Therapeutics, Inc.
P1
C
(37)
Moma-313
Metastatic Solid Tumor
MOMA Therapeutics
P1
C
(37)
Moma-341
Metastatic Solid Tumor
MOMA Therapeutics
P1
C
(37)
Msk-Tcr5
Metastatic Solid Tumor
Memorial Sloan Kettering Cancer Center
P1
C
(37)
Niraparib
Metastatic Solid Tumor
University of California, San Francisco
P1
C
(37)
Nvl-330
Metastatic Solid Tumor
Nuvalent Inc.
P1
C
(37)
Pemigatinib
Metastatic Solid Tumor
Massachusetts General Hospital
P1
C
(37)
pep07
Metastatic Solid Tumor
PharmaEngine
P1
C
(37)
Plx-61639
Metastatic Solid Tumor
Plexium, Inc.
P1
C
(37)
prt7732
Metastatic Solid Tumor
Prelude Therapeutics
P1
C
(37)
Pyrotinib
Metastatic Solid Tumor
BeiGene
P1
C
(37)
rc48-adc
Metastatic Solid Tumor
BeiGene
P1
C
(37)
Rosuvastatin
Metastatic Solid Tumor
Turning Point Therapeutics, Inc.
P1
C
(37)
sot201
Metastatic Solid Tumor
SOTIO Biotech AG
P1
C
(37)
Sotorasib
Metastatic Solid Tumor
Navire Pharma Inc., a BridgeBio company
P1
C
(37)
syn608
Metastatic Solid Tumor
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
P1
C
(37)
syn818
Metastatic Solid Tumor
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
P1
C
(37)
Tach101
Metastatic Solid Tumor
Tachyon Therapeutics, Inc.
P1
C
(37)
Tolododekin Alfa
Metastatic Solid Tumor
Ankyra Therapeutics, Inc
P1
C
(37)
Toripalimab
Metastatic Solid Tumor
Coherus Oncology, Inc.
P1
C
(37)
ty-2136b
Metastatic Solid Tumor
TYK Medicines, Inc
P1
C
(37)
Wm-A1-3389
Metastatic Solid Tumor
Wellmarker Bio
P1
C
(37)
Wtx-124
Metastatic Solid Tumor
Werewolf Therapeutics, Inc.
P1
C
(37)
xb628
Metastatic Solid Tumor
Exelixis
P1
C
(37)
Xirestomig
Metastatic Solid Tumor
Antengene (Hangzhou) Biologics Co., Ltd.
P1
C
(37)
Showing 101 to 125 of 132 assets
Previous
Page 5 of 6
Next